Context: In type 1 diabetes (T1D), delayed gastric emptying (GE) may predispose to a mismatch between insulin delivery and glucose absorption. Previous studies evaluated, only partly, the relationship between delayed GE and postprandial, but not diurnal, glycemia.
D
iabetes mellitus is associated with delayed and, to a lesser extent, rapid gastric emptying (GE) (1) . Delayed GE is associated with upper gastrointestinal symptoms, impaired quality of life, poor nutrition, and increased morbidity and mortality. Among 78 patients with type 1 diabetes (T1D) from the Epidemiology of Diabetes Interventions and Complications study, 47% had mostly asymptomatic, delayed GE (2) . This finding is important because there is a bidirectional relationship between glycemic disturbances and delayed GE (1) . Acute severe hyperglycemia delays GE in health and T1D. Conversely, delayed GE may impair glycemic control (3) . Therefore, the glycemic response to caloric intake is influenced by GE (4-7) and meal composition (8) . Pharmacologically mediated acceleration of GE increased postprandial glycemia in healthy people (4, 5) , T1D (9) , and type 2 diabetes (6, 10).
However, the effects of GE disturbances on glycemic control in T1D are poorly understood. In a study of 11 patients with T1D who were receiving insulin pump therapy, postprandial insulin requirements were lower for the first 120 minutes and greater between 180 and 240 minutes in 5 patients with gastroparesis than in 6 patients without (3) . However, blood glucose values during the postprandial period were not provided. In another study, GE was delayed in more patients with hypoglycemia [25 of 31 (81%)] than without [3 of 18 (17%)] (11) . Among 20 patients with diabetes, of whom 17 had T1D, blood glucose concentrations began to diverge between patients with normal and delayed GE starting at 1 hour postprandially, that is, concentrations declined in patients with delayed but not normal GE (12) . Three small studies either observed no change (13, 14) or improved glycemic control (15) in T1D patients treated with prokinetic agents. These studies did not evaluate glycemic variability with continuous glucose monitoring (CGM) (16) .
While postprandial glycemia accounts for a substantial proportion of overall glycemic control (17, 18) , the effect of abnormal GE on glucose control over the entire day is unknown. Toward the objective of improving glycemic control, CGM has been integrated with a continuous subcutaneous insulin infusion pump in a single unit (the sensor-augmented pump) and subsequently by the artificial pancreas, which is driven by a closed-loop algorithm (19, 20) . However, the dosing of prandial insulin is based on ingested carbohydrates or, in certain newer proposed artificial-pancreas algorithms, on the size of the meal, but not on GE or meal composition. This poses a potential pitfall, as nearly 50% of patients with T1D have delayed GE with the majority being asymptomatic (2) .
Intravenous erythromycin accelerates GE and is widely prescribed to hospitalized patients with diabetic gastroparesis with vomiting and dehydration (21) . The use of oral erythromycin for this purpose is supported by less evidence and limited by tachphylaxis (21) . Erythromycin may also increase small intestinal motility (22, 23) The main aims of this study were to (a) evaluate the association between the rate of GE and control of postprandial glycemia and over a longer duration of 10 days, as assessed by CGM in T1D; (b) assess the effects of intravenous erythromycin on GE and control of glycemia; and (c) assess the effects of oral erythromycin on GE and control of glycemia. Given the association of glycemic control with autonomic dysfunction in patients with diabetes, we also assessed the potential effects of observed vagal or sympathetic dysfunction in these studies. Our hypotheses were that (a) intravenous and oral erythromycin accelerate GE and increase early postprandial CGM glucose concentrations, and (b) delayed GE is associated with lower blood glucose concentrations soon after a meal.
Research Design and Methods

Study design and participants
Between June 2010 and July 2013, 30 patients with T1D consented to participate in this parallel-group study, which was approved by the Mayo Clinic Institutional Review Board, registered on clinicaltrials.gov (NCT02755064), and conducted at Mayo Clinic in Rochester, MN, between June 2010 and July 2013. All authors had access to the study data and had reviewed and approved the final manuscript. Of these patients, 13 were women; their ages ranged from 20 to 73 years [mean 6 standard error of the mean (SEM), 47 6 18 years], and their body mass index 6 SEM was 27.7 6 3.8 kg/m 2 . The inclusion criteria were T1D treated with a continuous subcutaneous insulin infusion delivered by an insulin pump with a glycosylated hemoglobin less than 8.5% (69 mmol/mol), and an estimated glomerular filtration rate greater than 60 mL/min per 1.73 m 2 . Exclusion criteria were substantial systemic (e.g., cardiovascular) disease that could potentially interfere with the objectives of the study or pose safety concerns, severe nausea or vomiting precluding study assessments, use of medications that alter gastrointestinal motility, and contraindications to erythromycin, including a prolonged corrected Q-T interval on electrocardiography.
At baseline, GE (GE baseline ) was assessed, the CGM sensor probe was inserted, and a log sheet was provided to keep track of meal times, insulin dosing, and glucose readings. At the second visit, GE was assessed after randomized administration of intravenous saline, erythromycin lactobionate 2 mg/kg, or 3 mg/kg (GE iv ). After a bolus of 0.5 mg/kg over 10 minutes immediately before the meal, the remaining erythromycin was infused over 50 minutes. In addition to standard dose of 3 mg/kg, a lower dose of 2 mg/kg was used to compare the relationship between GE and glycemia across a spectrum of GE rates (6, 24) . Thereafter, participants were randomized, stratified by the randomization during GE iv , to erythromycin ethyl succinate suspension (250 mg 3 times a day) or placebo for 7 days, followed by the third GE assessment (GE oral ), which was performed 30 minutes after the erythromycin dose. Compliance with oral erythromycin was confirmed from subject diaries. All patients completed the study within 11 days. (25, 26) with gas isotope ratio mass spectrometry. During GE iv , saline or erythromycin (2.0 or 3.0 mg/kg intravenously) infusions were started 10 minutes before the test meal.
Assessment of GE
There are 3 options for summarizing the GE data. (a) Percent dose excreted 31000 (kPCD), which is a mathematical expression of a test subject's 13 CO 2 excretion rate (per minute) at any measurement time t relative to the dose of 13 C contained in the test meal. kPCD values are recommended by the US Food and Drug Administration for determining normal or abnormal values (27) . (b) The estimated t half (half time), which is computed by multiple linear regression models derived from studies in which GE was simultaneously measured with [ 13 C]-Spirulina GE breath test (GEBT) and scintigraphy (25, 26) . The t half provides a single quantitative estimate of the entire GE curve (25, 26) . (c) Cumulative kPCD (ckPCD) values (i.e., area under the curve for kPCD values), which are proportional to the GE rate and approximate cumulative emptying from the stomach after a meal during scintigraphy. The normal values for the estimated t half for the GEBT meals used in this study were 50 to 97 minutes (entire range) (26) and 50 to 92 minutes (entire range) (25) .
In this study, GEBT data were summarized as the ckPCD values at all timepoints, similar to [
13 C]-based breath tests for other indications (e.g., breath tests for pancreatic insufficiency and Helicobacter pylori) (28) . For selected analyses, the GEBT data were also summarized as the t half .
Continuous glucose monitoring
A Medtronic iPRO Guardian (Medtronic) CGM sensor recorded glucose values every 5 minutes throughout the 10-day study period. This device was calibrated with fingerstick glucose readings 4 times a day, that is preprandially and at bedtime, or as instructed by the participant's physician using Medtronic One Touch meters provided as part of the study or their own glucometer. Postprandial glucose measurements were not routinely performed by all subjects. Participants were advised to continue taking insulin and other medications throughout the study as previously educated. CGM-based glucose data were analyzed without preprocessing. Based on recommendations (16), CGMbased glucose data were summarized as the proportion of time spent in different glycemic zones (,70, 70 to 180, .180 to 300, and .300 mg/dL). All patients used a continuous subcutaneous insulin infusion that delivered insulin at a basal rate determined by a diabetologist in clinical practice, typically 3 to 5 units over 6 hours, and boluses based on carbohydrate consumption. The insulin pump settings were adjusted by clinical endocrinologists within 3 months prior to enrollment. During the study, only 6 of 30 patients used dual or square wave boluses. Five of those 6 patients used square wave or dual boluses for less than 10% of the time. Only bolus doses were considered for analyzing insulin effects (29) .
Calorie consumption
All subjects were provided 3 meals per day for the duration of the study from the metabolic kitchen in the Clinical Research and Trials Unit at Mayo Clinic. The meals were composed of carbohydrates (50%), fats (30%), and proteins (20%). On the 3 study days on which a GE study was performed, the GEBT meal contained 223 kcal; the remaining calories were evenly split between lunch and dinner. On the remaining days, the distribution of calories was 30%, 30%, and 40% for respectively breakfast, lunch, and dinner. To facilitate insulin dosing, a written copy of the menu and the carbohydrate content for each meal was also provided to all participants. Caloric intake was calculated from dietary logs that included all caloric intake (i.e., provided meals and additional snacks).
Symptom questionnaires
Gastrointestinal symptoms were evaluated with the patient assessment of upper gastrointestinal symptom severity index questionnaire (30) .
Autonomic function testing
Cardiovagal function was assessed by measuring heart rate and blood pressure responses to deep breathing and the Valsalva maneuver (31) and by quantitating both the vagal and the adrenergic components of baroreflexes.
Statistical analyses
Treatment assignments (balanced on age, sex, and body mass index) with a block size of 6 were generated by computer. Study personnel were blinded to drug assignments and GE results until the study was completed. A sample size of 30 subjects was estimated to provide approximately 80% power to detect a univariate (linear) correlation between GE responses (e.g., t half ) and CGM summary measures [e.g., overall within-subject standard deviation (SD) of r = 0.47, or greater; 2-sided a level of 0.05]. The linear regression models will provide estimates demographic and clinical features were compared with the Student t test or Wilcoxon test, as appropriate. Data are presented as mean 6 SEM unless stated otherwise. Univariate associations between GE (i.e., ckPCD values), glycemia, insulin dose, and carbohydrate intake were assessed with Spearman correlation coefficients. Data from CGM were used as is and were also summarized with conventional measures, that is, SD of blood glucose differences, low and high BG indices (LBGI and HBGI, respectively), blood glucose risk index (blood glucose risk index, i.e., LBGI + HBGI), mean absolute glucose change, and coefficient of variability (32) .
A mixed-model analysis evaluated the contribution of carbohydrate consumption, insulin dose, and GE t half to mean glucose values, which was the dependent variable over all 10 days. For this analysis, the insulin dose, carbohydrate consumption, and mean glucose value were summarized for 4 periods every day (i.e., 12 AM to 7 AM, 7 AM to 1 PM, 1 PM to 7 PM, and 7 PM to 12 AM) for the entire study. In these models, GE t half values estimated with GE baseline , GE iv , and GE oral were used, respectively, for days 1 and 2 (i.e., baseline), day 3 (i.e., GE iv day), and days 4 through 10 (i.e., during treatment with oral erythromycin or placebo). Because most patients completed the study at approximately 1 PM after the last breath collection for GE oral , 38 (i.e., 40 2 2) time periods were analyzed.
The effect of erythromycin on ckPCD values was assessed in a mixed-effects model on the difference between GE iv and GE baseline and, separately, GE oral and GE baseline . Another mixed model with an autoregressive covariance structure (33) that incorporated CGM-based glucose values, GE baseline , and erythromycin assessed the relationship among GE, glycemia, and treatment during the postprandial period (3 hours after the meal). Because erythromycin perturbs GE, these models incorporated ckPCD (i.e., at all 8 time points from 15 to 180 minutes), rather than a CGMbased glucose value, as the dependent variable. Variables were log transformed as appropriate. For GE baseline , this model also incorporated a variable for insulin effect. For GE iv and GE oral , this variable was not significant and, hence, was excluded from the final model. All statistical analyses were performed in SAS and JMP 11.0 (SAS Institute Inc., Cary, NC).
The
Results
Demographic and clinical features
All patients completed study procedures (Supplemental Fig. 1 ). The diabetes duration was 26 6 13 years; glycosylated hemoglobin was 7.6% 6 0.8% (60 6 8.7 mmol/mol). Complications included peripheral neuropathy (6 patients) and retinopathy (16 patients). Autonomic testing revealed cardiovagal dysfunction in 11 patients, of whom 2 had delayed GE at baseline. One patient had cardiac sympathetic dysfunction and delayed GE. Hence, 14 patients had peripheral or autonomic neuropathy.
The demographic and clinical features were not significantly different between the erythromycin and placebo groups during GE iv (intravenous treatment) or GE oral (oral treatment; Table 1 ). Based on the patient assessment of upper gastrointestinal disorders symptom severity index questionnaire, 10 patients had no GI symptoms. The remainder had very mild (9), mild (5), moderate (3), or severe (2) GI symptoms. One patient reported nausea, heartburn, and diarrhea while on medication.
Relationship of glycemia to carbohydrate intake, insulin use, and GE for the entire study
The median insulin dose, CGM-based glucose value, and carbohydrate consumption for the entire study are shown in Fig. 1 . Within each time period, the insulin dose was correlated with the carbohydrate consumption (r = 0.81, P , 0.001) and with the CGM-based glucose value (r = 0.30, P , 0.001). Carbohydrate consumption was correlated with the mean CGM-based glucose value (r = 0.13, P , 0.001) for the same time period and inversely correlated (r = 20.16, P , 0.001) with the CGM-based glucose value during the following period.
In the multiple-variable model, the mean glucose value over the entire study was directly associated with insulin dose and GE t half and inversely correlated with carbohydrate consumption ( Table 2 ). The parameter estimates in this model suggest that, on average, each 10% increase in carbohydrate consumption, insulin dose, and GE t half , respectively, was associated with a 1.7% reduction (i.e., 
Effect of erythromycin on GE
The t half values suggest that GE was delayed in 12 patients (40%) at GE baseline , in 9 patients (30%) at GE iv , and in 12 patients (40%) at GE oral ; the remainder had normal GE. The GE baseline t half was 65 6 18 minutes among those with normal GE, and 113 6 13 minutes among those with delayed GE.
Compared with placebo, intravenous erythromycin (3 mg/kg, but not 2 mg/kg) increased the ckPCD value at 60 minutes (P = 0.03), signifying faster early GE, but not the t half (Fig. 2) . Drug effects on GE, as assessed by the difference in estimated t half and ckPCD values between GE iv and GE baseline , were negatively correlated (r = 20.59, P , 0.001; Fig. 3 ). In contrast, oral erythromycin did not affect the t half or ckPCD values during GE oral (Fig. 2) .
Relationship between GE and CGM-based glucose value
The fasting CGM-based glucose value was 157 6 13 mg/dL before GE baseline , 180 6 10 mg/dL before GE iv , and 194 6 15 mg/dL before GE oral . During GE iv and GE oral , these values were not significantly different among treatment groups (Table 1) . Only 1 patient at GE baseline and 3 patients at GE oral had a fasting blood glucose greater than the recommended value of 275 mg/dL.
These fasting glucose concentrations were correlated with the peak postprandial CGM-based glucose value during the GEBT of study 1 (r = 0.79, P , 0.001), 2 (r = 0.83, P , 0.001), and 3 (r = 0.79, P , 0.001). The mean 6 SD intraindividual differences in fasting CGM-based glucose values were 21 6 92 mg/dL for GE iv -GE baseline and 27 6 98 mg/dL for GE oral -GE baseline , reflecting considerable variation in fasting CGM-based values among subjects. Fasting glucose value was not correlated with the GE ckPCD values during GE baseline , GE iv , and GE oral . During GE baseline , GE iv and GE oral , GE t half was not associated with SD, LBGI, HBGI, and blood glucose risk index derived from CGM.
The multiple-variable models evaluating the relationship between GE and glucose, expressed as a continuous variable, during GE baseline , GE iv , and GE oral are shown in Table 2 . At GE baseline , time, glucose, and the insulin dose parameter independently predicted the ckPCD values. The ckPCD values increased over time. The parameter estimates suggest that each 10% increase in CGM glucose concentration and the measure of insulin effect (i.e., dose/ duration since last dose) were, respectively, associated with a 9% increase and a 2% decrease in ckPCD values.
During GE iv , the ckPCD values were explained by the ckPCD values during GE baseline , glucose value 1, 2, 3, and 4 are from midnight to 7 AM, 7 AM to 1 PM, 1 PM to 7 PM, and 7 PM to midnight, respectively. GE was categorized as normal or delayed based on the results of GE baseline for days 1 and 2, GE iv for day 3, and GE oral for days 3 to 10.
during GE iv , treatment group (i.e., erythromycin 3 mg/kg but not 2 mg/kg intravenously), and an interaction term (time 3 treatment; Table 2 ). Greater ckPCD values reflect faster GE. Hence, erythromycin (3 mg/kg) was associated with faster GE, which was associated with higher postprandial CGM-based glucose values. The interaction term suggests that erythromycin modified the temporal profile of GEBT ckPCD values. Except for CGM-based glucose values, these predictors, including treatment, were also significant during GE oral ( Table 2) .
The relationship between GE and CGM-based glucose value was also analyzed by summarizing CGM-based values into categories. During GE baseline , the estimated t half was inversely associated (r = 20.38, P , 0.05) with the proportion of time the CGM-based glucose value was greater than 300 mg/dL. Expressed differently, faster GE was associated with the duration for which the glucose value was more than 300 mg/dL. During GE baseline , GE iv , and GE oral , associations between t half and proportion of time CGM-based glucose were ,70 mg/dL, 70 to 180 mg/dL, or 180 to 300 mg/dL were not significant. During GE iv , the rate of increase from fasting to peak postprandial CGM-based glucose concentrations was greater in patients who received erythromycin 3 mg/kg than placebo (P , 0.05; Fig. 4) . During GE oral , the rate to peak glucose was directly associated with ckPCD at 15 (r = 0.50), 30 (r = 0.46), 45 (r = 0.45), and 60 minutes (r = 0.39, P , 0.05), that is, when the ckPCD was lower, reflecting slower GE, the rate at which the CGM-based glucose value increased was lower (Fig. 4) .
Discussion
Through a rigorous experimental design that integrated an assessment of GE on 3 separate occasions, CGM, insulin delivery with a pump, and standardized meals comprising a weight-maintaining diet, this study evaluated the effect of modulating GE on CGM-based glycemic control in 30 patients with T1D on an insulin pump. Comparable to other studies in T1D, 40% of the patients had delayed GE at baseline; most had no or relatively mild GI symptoms (2, 34) . GE rates spanned a spectrum and severe GI symptoms were uncommon, allowing us to press.endocrine.org/journal/jcemfocus on the relationship between GE and glycemic control, without the confounding effects of markedly fluctuating caloric intake. Intravenous erythromycin 3 mg/kg but not 2 mg/kg accelerated the GE of solids (24) . Oral erythromycin suspension administered at the recommended dose did not accelerate GE, perhaps because of tachyphylaxis (35) or hyperglycemia, which attenuate the effects of erythromycin on GE (36, 37) .
Greater ckPCD values (i.e., faster GE) were independently associated with greater CGM-based glucose values during GE baseline and GE iv ( Table 2 ), suggesting that faster GE accelerated the duodenum delivery and glucose absorption. Although oral erythromycin did not significantly accelerate GE, the GEBT ckPCD values at 15, 30, 45, and 60 minutes were all correlated with the rate of increase in CGM-based glucose. Other mechanisms (e.g., increased hepatic glucose release) are unlikely to explain erythromycin induced increased postprandial glycemia (38) . However, the lack of endogenous insulin secretion in response to rapid GE may contribute to hyperglycemia in T1D.
By contrast, delayed GE was associated with higher CGM-based glucose concentrations across the entire study. There are 3 possible explanations. First, when GE is delayed, the effects of preprandial insulin may wane when glucose is absorbed, predisposing to increased glycemia. Indeed, among patients with T1D treated with an artificial pancreas device, insulin requirements over 180 to 240 minutes after a meal were higher in patients with delayed than normal GE (3). Further, among T1D patients with pramlintide-induced delayed GE, the rate of appearance of meal-derived glucose-induced delayed GE was reduced between 15 and 90 minutes but increased thereafter (39, 40) . Second, hyperglycemia may delay GE (41) . Third, longstanding T1D is associated with reduced secretion of amylin (39) , with impaired postprandial inhibition of glucagon secretion, and increased hepatic glucose output.
What are the clinical implications? First, slower GE was not associated with a postprandial CGM-based glucose less Relationship between the difference in estimated t half and ckPCD value at 60 minutes for GE iv -GE baseline . A greater difference (GE iv -GE baseline ) in ckPCD values at 60 minutes was inversely correlated (r = 20.59, P , 0.001) with the GEBT t half . Greater ckPCD values and a lower t half reflect accelerated GE.
than 70 mg/dL. Because only 12 patients had delayed GE at baseline, the analysis evaluated GE on a continuous scale. Second, the impact of delayed GE on glucose concentration can be estimated. The difference between the mean (45 minutes) and 90th percentile values (97 minutes) for GEBT t half among healthy people in a previous study (26) was approximately 115%. Here (Table 2) , a 115% increase in GEBT t half was associated with a 6% (i.e., 2.15 0.07 = 1.06) increase in mean glucose over the entire day. This is approximately equivalent to the effect of a 15% increase (calculated by 1.15 0.20 = 1.06) in insulin dose.
Hence, the glucose increment associated with delayed GE is, at a minimum, equivalent to that requiring 15% more insulin. In the postprandial model, the parameter estimate for erythromycin's (3 mg/kg intravenously) treatment effect was 0.3 6 0.1. Applying this value, the difference in GE between placebo and erythromycin was ;35%, because e 0.3 = 1.35. The GE baseline model for the postprandial period, suggests that accelerating GE by 35% is associated with a 40% greater CGM glucose, because 1.4 0.89 = 1.35, where 0.89 is the parameter estimate for CGM glucose in this model. Hence, the acceleration in GE after erythromycin (3 mg/kg intravenously) is estimated to be associated with an increase in CGM glucose by ;40%. Third, perhaps patients with delayed GE should inject their mealtime insulin later to prevent early hypoglycemia and late hyperglycemia. Four, erythromycin increased postprandial CGM glucose but did not cause postprandial hyperglycemia, albeit after a meal with 19.2 g of carbohydrates. The effects of a ghrelin agonist that accelerates GE in T1D without tachyphylaxis should be evaluated (42) . These findings apply to a cohort of patients with T1D and relatively mild symptoms. Further studies in a larger cohort of patients with T1D and more severe upper GI symptoms are necessary.
In conclusion, delayed GE was not associated with postprandial hypoglycemia or increased glycemic variability in T1D. Faster GE was associated with greater and lower CGM-based glucose values during the postprandial period and the entire study, respectively. press.endocrine.org/journal/jcem
